Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Exerts Neurotoxicity in Models of Parkinson's Disease.

Molecular neurobiology - 1 Nov 2017

Wu Qimei, Yang Xiaoyu, Zhang Lei, Zhang Yu, Feng Linyin

Abstract excerpt

Histone deacetylase 4 (HDAC4) is a class II HDAC which is highly expressed in the brain. Previous reports have shown that HDAC4 is essential for normal brain physiology and its deregulation leads to several neurodegenerative disorders. However, it remains unclear whether dysregulation of HDAC4 is specifically involved in the development of Parkinson's disease. In this study, we demonstrate that intracellular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Cyclic AMP Response Element-Binding Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopaminergic Neurons

Share to Histone Deacetylases

Share to MEF2 Transcription Factors

Share to Neurotoxins

Share to PC12 Cells

Share to Protein Kinase C-epsilon

Source

Identifiers

PMID: 27785754
DOI: 10.1007/s12035-016-0199-2

Genes

HDAC4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Exerts Neurotoxicity in Models of Parkinson's Disease.PMID 27785754Read ↗

HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievementsSemantic proximity Read ↗

The class II histone deacetylases as therapeutic targets for Parkinson’s diseaseSemantic proximity Read ↗

Targeting Histone Deacetylases: A Novel Approach in Parkinson’s DiseaseSemantic proximity Read ↗

Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future PerspectiveSemantic proximity Read ↗

Histone Deacetylase 4 Inhibition Reduces Rotenone-Induced Alpha-Synuclein Accumulation via Autophagy in SH-SY5Y CellsSemantic proximity Read ↗

HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?Semantic proximity Read ↗

LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's diseaseSemantic proximity Read ↗

HDACs in the Brain: From Chromatin Remodeling to Neurodegenerative DiseaseSemantic proximity Read ↗

Epigenetics in Neurodegenerative Diseases: The Role of Histone DeacetylasesSemantic proximity Read ↗

Histone deacetylases as targets for the treatment of human neurodegenerative diseasesSemantic proximity Read ↗

HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration.Semantic proximity Read ↗

Regional and subcellular distribution of HDAC4 in mouse brainSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.